Search research articles
Contact Us
Filters
Showing results (61-70 of 68) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 68 results.
Revue Neurologique
|
July 11, 2009
[Atypical progressive multifocal leukoencephalopathy (PML) in a patient with pulmonary sarcoidosis]
J Le Guilloux, C Roubiou, J Mallet, et al.
The Annals of Thoracic Surgery
|
July 1, 1994
Long-term effects of dynamic aortomyoplasty
J C Chachques, F Haab, C Cron, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 22, 2008
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies
J Honnorat, S Cartalat-Carel, D Ricard, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
December 1, 1996
Long-term outcome, survival analysis, and risk stratification of dynamic cardiomyoplasty
A P Furnary, J C Chachques, L F Moreira, et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|
July 27, 2000
[Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists]
D Plantaz, J Michon, D Valteau-Couanet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2004
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions
K Hoang-Xuan, L Capelle, M Kujas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2019
Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study
R Ursu, L Thomas, D Psimaras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
M J van den Bent, W Grisold, D Frappaz, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 68) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 68 results.
Revue Neurologique
|
July 11, 2009
[Atypical progressive multifocal leukoencephalopathy (PML) in a patient with pulmonary sarcoidosis]
J Le Guilloux, C Roubiou, J Mallet, et al.
The Annals of Thoracic Surgery
|
July 1, 1994
Long-term effects of dynamic aortomyoplasty
J C Chachques, F Haab, C Cron, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 22, 2008
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies
J Honnorat, S Cartalat-Carel, D Ricard, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
December 1, 1996
Long-term outcome, survival analysis, and risk stratification of dynamic cardiomyoplasty
A P Furnary, J C Chachques, L F Moreira, et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|
July 27, 2000
[Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists]
D Plantaz, J Michon, D Valteau-Couanet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2004
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions
K Hoang-Xuan, L Capelle, M Kujas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2019
Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study
R Ursu, L Thomas, D Psimaras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
M J van den Bent, W Grisold, D Frappaz, et al.
Page
of 7